Shelby D. Reed, PhD, is a professor in population health sciences at the Duke University School of Medicine. She works primarily at the Duke Clinical Research Institute. Dr. Reed holds a PhD in pharmaceutical health services research from the University of Maryland School of Pharmacy and completed a 2-year postdoctoral fellowship in the Pharmaceutical Outcomes Research and Policy Program and the Center for AIDS Research at the University of Washington. Dr. Reed has nearly 20 years of experience in economic evaluation, health services research and health policy. Dr. Reed has extensive expertise in designing and conducting trial-based and model-based cost-effectiveness analyses of medical diagnostics and interventions in numerous therapeutic areas. She was a member of the ISPOR Task Forces that published recommendations for Good Research Practices for Cost-Effectiveness Analysis Alongside Clinical Trials in 2005 and 2015. She has led a wide range of economic and epidemiological studies using secondary data from health care claims, clinical trials, surveys and disease registries. In her evaluations of health policy issues, she has developed computer models to analyze the potential economic impact of trends in clinical trial design, changes in reimbursement policies, financial incentives and the regulatory process in the development of orphan drugs, and the societal value of alternative approaches to identifying drug safety problems. Over the last several years, her research has increasingly focused on stated-preference studies to evaluate benefit-risk tradeoffs, patient-centered value, and their application in comparative effectiveness research and clinical decision making.
Mentz RJ, Whellan DJ, Reeves GR, Pastva AM, Duncan P, Upadhya B, et al. Rehabilitation Intervention in Older Patients With Acute Heart Failure With Preserved Versus Reduced Ejection Fraction. Jacc Heart Failure. 2021 Oct;9(10):747–57.
Reed SD, Yang J-C, Gonzalez JM, Johnson FR. Quantifying Value of Hope. Value Health. 2021 Oct;24(10):1511–9.
Gonzalez JM, Reed SD, Johnson FR. Stratified psoriasis treatment plans: why is patient preference information needed? Br J Dermatol. 2021 Aug 31;